Ticker

There's no shortage of stocks that provide risk-tolerant traders with excitement. Plenty of ETFs accomplish that objective, too.

KORU Medical Systems is transforming into a digitally enabled drug delivery platform, leveraging secular tailwinds in at-home subcutaneous infusion therapies. Q2 revenue grew 18.2% to $12.05M with positive net income and gross margin expansion to 65.1%, driven by domestic core strength and international growth. International ramp is slower than forecast, prompting narrowed FY guidance to $47.5M–$48.5M revenue and a…

The Direxion Daily MSCI South Korea Bull 3X ETF (KORU) has fallen 73% from its highs while the KOSPI dropped 38%, even though SK Hynix's operating profit grew 500% in the same period. The KOSPI's forward P/E fell to 4.5x and its earning yield rose to 22%, driven mainly by forced margin call liquidations rather than weaker earnings. FLKR's daily RSI has already shown a V-shaped recovery near the 30 level, signaling…

KORU Medical Systems NASDAQ: KRMD reported second-quarter revenue of $12 million, up 18% from a year earlier, as domestic patient starts, market-share gains and international demand supported growth. The company also said it achieved positive net income for the first time since 2019 and raised its full-year gross-margin outlook, while narrowing revenue guidance because certain international prefilled-syringe market…

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year…